Scroll To Top
Issue Features

Tips+Tools

Tips+Tools

Cover64_100_8

The next major advance in simplification of treatment could be the approval of antiretrovirals in nanosuspension formulations that release drug molecules slowly, and thus may enable once-monthly'or even less frequent'injectable antiretroviral therapy. A Tibotec Therapeutics experimental nonnuke, rilpivirine (TMC278), is the compound furthest along in the development of this technology, according to research released at the 15th Conference on Retroviruses and Opportunistic Infections.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.